Skip to main content

Table 1 FDA approved therapeutic monoclonal antibodies for cancer therapy

From: Targeted drug delivery for cancer therapy: the other side of antibodies

Generic name Proprietary name Target Technology Isotype Additional manipulations Year FDA approved Approved clinical indication
Rituximab Rituxin®/ Mabthera® CD20 Mouse Hybridoma IgG1-kappa Chimeric 1997 NHL; later CD20+CLL, FL, RA
Transtuzumab Herceptin® HER-2 Mouse Hybridoma IgG1-kappa Humanized 1998 HER-2+ MBC
Alemtuzumab Campath®/ Mabcampath® CD52 Rat Hybridoma IgG1-kappa Humanized 2001 CL L, T-cellLymphoma
Ibritomomab tiuxitan Zevalin® CD20 Mouse monoclonal IgG1-kappa Conjugated to Yittrium-90 2002 NHL
Tositumomab Bexxar® CD20 Mouse monoclonal IgG2a-lambda Conjugated to I-131 2003 NHL
Cetuximab Erbitux® EGRF, HER-1 Mouse monoclonal IgG1- kappa Chimeric 2004 EGRF+ MCC
Bevacizumab Avastin® VEGF Mouse monoclonal IgG1- kappa Humanized 2004 MCC
Panitumumab Vectibix™ EGRF, HER-1 Human monoclonal IgG2-kappa Human 2006 MCC
Ofatumumab Arzerra™ CD20 Human monoclonal IgG1-kappa Human 2009 Refractory CLL
Ipilimumab Yervoy™ CTLA-4 Human monoclonal IgG1-kappa Human 2011 MMel
Pertuzumab Perjeta™ EGFR2, HER-2 Mouse monoclonal IgG1-kappa Humanized 2012 BC
  1. BC, Breast cancer; MBC_Metastatic breast cancer; NHL, Non-Hodgkin's Lymphoma; CLL, Chronic Lymphocytic leukemia; FL, Follicular Leukemia; RA, Rhematoid arthritis; MCC, Metastatic colorectal cancer; MMel, metastatic melanoma.